HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Mark R Olsen Selected Research

Fatigue

2/2015Quality of life analyses from the randomized, open-label, phase III PointBreak study of pemetrexed-carboplatin-bevacizumab followed by maintenance pemetrexed-bevacizumab versus paclitaxel-carboplatin-bevacizumab followed by maintenance bevacizumab in patients with stage IIIB or IV nonsquamous non-small-cell lung cancer.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Mark R Olsen Research Topics

Disease

4Renal Cell Carcinoma (Grawitz Tumor)
01/2022 - 04/2012
3Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
05/2015 - 12/2013
2Neoplasms (Cancer)
02/2015 - 04/2012
1Brain Neoplasms (Brain Tumor)
01/2022
1Fatigue
02/2015
1Disease Progression
12/2013

Drug/Important Bio-Agent (IBA)

3NivolumabIBA
01/2022 - 12/2020
3Bevacizumab (Avastin)FDA Link
05/2015 - 12/2013
3Pemetrexed (MTA)FDA Link
05/2015 - 12/2013
3Carboplatin (JM8)FDA LinkGeneric
05/2015 - 12/2013
3Paclitaxel (Taxol)FDA LinkGeneric
05/2015 - 12/2013
1IpilimumabIBA
01/2022
1Sunitinib (Sutent)FDA Link
04/2012

Therapy/Procedure

2Therapeutics
02/2015 - 04/2012